Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Spirapril. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE known ✓ | P12821 | 14/20 | 0.82 |
| ▸ | ABCB11 | O95342 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Spirapril SCHEMBL7340705 | 1.00 | ABCB11 (1.00) | ABCB11ACELMNASMN1; SMN2PDE3A | |
| Spirapril SCHEMBL14660503 | 1.00 | ABCB11 (1.00) | ABCB11ACELMNASMN1; SMN2PDE3A | |
| Spirapril SCHEMBL3975621 | 0.99 | ABCB11 (0.98) | ABCB11ACELMNASMN1; SMN2PDE3A | |
| Spirapril SCHEMBL7338589 | 0.99 | ABCB11 (0.98) | ABCB11ACELMNASMN1; SMN2PDE3A | |
| Spirapril SCHEMBL3785516 | 0.99 | ABCB11 (0.98) | ABCB11ACELMNASMN1; SMN2PDE3A | |
| Spirapril SCHEMBL1649585 | 0.99 | ABCB11 (0.98) | ABCB11ACELMNASMN1; SMN2PDE3A | |
| Spirapril SCHEMBL11052621 | 0.99 | ABCB11 (0.98) | ABCB11ACELMNASMN1; SMN2PDE3A | |
| Spirapril SCHEMBL17202 | 0.99 | ABCB11 (0.98) | ABCB11ACELMNASMN1; SMN2PDE3A | |
| Spirapril SCHEMBL6506406 | 0.99 | ABCB11 (0.98) | ABCB11ACELMNASMN1; SMN2PDE3A | |
| Spirapril SCHEMBL11052614 | 0.99 | ABCB11 (0.98) | ABCB11ACELMNASMN1; SMN2PDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1017 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10149909-B2 | Fortifier | TORAY INDUSTRIES, INC. (JP) | 2018-12-11 | — | — | US | claimed |
| US-20180118699-A1 | SK AND IK CHANNEL AGONISTS FOR TREATMENT OF HEART FAILURE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2018-05-03 | — | — | US | claimed |
| EP-2480224-B1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF MCP-1 MEDIATED INFLAMMATORY DISEASES | ACRAF (IT) | 2017-05-24 | — | — | EP | claimed |
| US-20170080089-A1 | FORTIFIER | TORAY INDUSTRIES, INC. (JP) | 2017-03-23 | — | — | US | claimed |
| WO-2016191294-A1 | SK AND IK CHANNEL AGONISTS FOR TREATMENT OF HEART FAILURE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2016-12-01 | — | — | WO | claimed |
| EP-2205639-B1 | ANTI-PCSK9 AND METHODS FOR TREATING LIPID AND CHOLESTEROL DISORDERS | MERCK SHARP & DOHME (US) | 2015-12-23 | — | — | EP | claimed |
| US-20150352094-A1 | USE OF FATTY ACID NIACIN CONJUGATES FOR TREATING DISEASES | CATABASIS PHARMACEUTICALS, INC. | 2015-12-10 | — | — | US | claimed |
| EP-2941252-A2 | USE OF FATTY ACID NIACIN CONJUGATES FOR TREATING DISEASES | Catabasis Pharmaceuticals, Inc. (US) | 2015-11-11 | — | — | EP | claimed |
| WO-2014107730-A2 | USE OF FATTY ACID NIACIN CONJUGATES FOR TREATING DISEASES | CATABASIS PHARMACEUTICALS, INC. (US) | 2014-07-10 | — | — | WO | claimed |
| US-20140161798-A1 | ANTI-PCSK9 AND METHODS FOR TREATING LIPID AND CHOLESTEROL DISORDERS | MERCK SHARP & DOHME CORP. (US) | 2014-06-12 | — | — | US | claimed |
| EP-1385548-A2 | COMBINATIONS OF STEROL ABSORPTION INHIBITOR(S) WITH CARDIOVASCULAR AGENT(S) FOR THE TREATMENT OF VASCULAR CONDITIONS | Schering Corporation (US) | 2004-02-04 | — | — | EP | claimed |
| US-20030069221-A1 | Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions | SCHERING CORPORATION | 2003-04-10 | — | — | US | claimed |
| US-20020198165-A1 | Nucleic acids for the prevention and treatment of gastric ulcers | COLEY PHARMACEUTICAL GROUP, INC. | 2002-12-26 | — | — | US | claimed |
| CN-1384756-A | Pharmaceutical formulations and their use in the prevention of stroke, diabetes and/or congestive heart failure | AVENTIS PHARMA GMBH (DE) | 2002-12-11 | — | — | CN | claimed |
| WO-2002058731-A2 | COMBINATIONS OF STEROL ABSORPTION INHIBITOR(S) WITH CARDIOVASCULAR AGENT(S) FOR THE TREATMENT OF VASCULAR CONDITIONS | SCHERING CORPORATION (US) | 2002-08-01 | — | — | WO | claimed |
| EP-0876158-B1 | NOVEL MEDICAL USE OF AN ACE-INHIBITOR FOR TREATMENT OF DYSPEPTIC SYMPTOMS | PHARMACORE AB (SE) | 2002-06-12 | — | — | EP | claimed |
| EP-1212081-A2 | PHARMACEUTICAL FORMULATIONS AND USE THEREOF IN THE PREVENTION OF STROKE, DIABETES AND/OR CONGESTIVE HEART FAILURE | Aventis Pharma Deutschland GmbH (DE) | 2002-06-12 | — | — | EP | claimed |
| WO-2001015673-A2 | PHARMACEUTICAL FORMULATIONS AND USE THEREOF IN THE PREVENTION OF STROKE, DIABETES AND/OR CONGESTIVE HEART FAILURE | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-03-08 | — | — | WO | claimed |
| US-5977159-A | Medical use of an ace-inhibitor for treatment of dyspeptic symptoms | ASTRA AKTIEBOLAG (SE) | 1999-11-02 | — | — | US | claimed |
| US-4470972-A | 7-Carboxyalkylaminoacyl-1,4-dithia-7-azaspiro[4.4]-nonane-8-carboxylic acids | SCHERING CORPORATION (US) | 1984-09-11 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10149909-B2 | Fortifier | REN, ACE, AGT | ACE 2/4885ABCB11 477/4885LMNA 1587/4885 |
| US-20170080089-A1 | FORTIFIER | REN, ACE, AGT | ACE 2/4885ABCB11 477/4885LMNA 1587/4885 |
| US-20030069221-A1 | Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions | CYP46A1, FABP2, SREBF1 | ACE 357/4885ABCB11 58/4885LMNA 1488/4885 |
| US-20150352094-A1 | USE OF FATTY ACID NIACIN CONJUGATES FOR TREATING DISEASES | NAMPT, NNT, FASN | ACE 1402/4885ABCB11 744/4885LMNA 970/4885 |
| US-20140161798-A1 | ANTI-PCSK9 AND METHODS FOR TREATING LIPID AND CHOLESTEROL DISORDERS | PCSK9, PCSK7, CETP | ACE 126/4885ABCB11 828/4885LMNA 326/4885 |
| US-20180118699-A1 | SK AND IK CHANNEL AGONISTS FOR TREATMENT OF HEART FAILURE | KCNH2, KCNK5, KCNN3 | ACE 1785/4885ABCB11 289/4885LMNA 1847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.